Fig. 3: Survival outcomes by race for patients treated with RVd versus D-RVd. | Blood Cancer Journal

Fig. 3: Survival outcomes by race for patients treated with RVd versus D-RVd.

From: Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

Fig. 3: Survival outcomes by race for patients treated with RVd versus D-RVd.

A Median progression-free survival (PFS) in white patients treated with D-RVd versus RVD. B Median progression-free survival (PFS) for black patients treated with D-RVD versus RVD.

Back to article page